<DOC>
	<DOCNO>NCT00189371</DOCNO>
	<brief_summary>Patients epithelial ovarian cancer , fallopian tube peritoneal cancer receive surgical cytoreduction platinum/taxane contain chemotherapy significant chance enter complete clinical remission 70 % eventually relapse . Relapse 6 month follow first line chemotherapy regard platinum/taxane sensitive disease . Reinduction chemotherapy platinum/taxane know effective treatment option . Therapy induce anemia common problem result decrease quality life . The rationale trail evaluate effect epoetin alpha reduction therapy induce anemia , rate transfusion quality life .</brief_summary>
	<brief_title>Reinduction Chemotherapy Containing Carboplatin Paclitaxel With Without Epoetin Alpha Recurrent Platinum Sensitive Ovarian Cancer , Cancer Fallopian Tube Peritoneum</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Relapse longer 6 month termination platinum/taxane base first line chemotherapy Previously histologically confirm cancer : ovary , fallopian tube , peritoneum measurable evaluable lesion ultrasound , computertomography MRI Performance status ECOG &lt; 2 karnofsky index &gt; 60 % normal organ function 1 chemotherapy prior enrollment ongoing treatment epoetin alpha relate drug history thrombosis embolism past 12 month prior enrollment ileus leave ventricular failure &gt; NYHA classification &gt; 2 Ongoing toxicity kind ( &gt; CTC Grad II )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>